U.S. Marine and Shipping Stock News

RBC Capital recently downgraded ResMed to Sector Perform from Outperform, pointing to FY27 pressures from Astral ventilator replacements, higher input costs, and supply constraints on key components. The downgrade highlights how operational issues in a single product line can ripple through device sales, cost structure, and overall business planning for the coming years. Next, we’ll examine how expected FY27 cost pressures and supply bottlenecks may influence ResMed’s previously optimistic...

Resideo Technologies has nearly doubled investors' money over the past three years, and the current valuation checks suggest the stock still trades at a discount, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating room above the recent US$35.83 share price. Resideo Technologies has returned 98.4% over the past three years, which puts extra focus on whether that gain is fully backed by fundamentals. The planned spin off of the ADI Global Distribution business may support...

Voter support is tilting toward democratic socialist policies like universal healthcare, higher taxes on the wealthy, and more government-backed services, and that puts parts of the healthcare sector squarely under the spotlight. For investors, the bigger question is how potential future reforms and tougher oversight could affect margins, pricing power, and long term business models. This article examines the political catalysts behind this shift and then outlines 3 healthcare stocks that...

Assurant stock has delivered a strong 124.2% return over the past three years, yet the valuation picture is split, with the Excess Returns intrinsic value estimate pointing to meaningful upside while market multiples suggest the shares trade at a premium. Over three years, Assurant has returned 124.2%, which puts extra focus on whether today’s price still leaves room for attractive risk adjusted returns. Upcoming earnings, where analysts expect pressure on EPS, may influence views on the...

Ameris Bancorp (ABCB) heads into its next earnings report on July 23 with expectations for higher year over year earnings and revenue, putting fresh attention on how the stock prices in those forecasts. See our latest analysis for Ameris Bancorp. The recent 7 day share price return of 2.10% and 30 day share price return of 7.32% suggest momentum has been building in Ameris Bancorp ahead of its earnings update. At the same time, the 1 year total shareholder return of 38.48% and 3 year total...

Target Hospitality stock has delivered a very large 359.6% total return over the past five years, yet the current valuation checks lean expensive, with a low overall value score and market multiples that screen as overvalued. A 359.6% five year return means long term shareholders have already seen substantial gains, so fresh buyers are coming in after a strong run. Future contract wins and utilization levels can support earnings and cash flow, but any disappointment in occupancy or pricing...

Trump Media & Technology Group’s plan to charge up to US$100,000 per month for high speed API access to President Trump’s Truth Social posts is turning market information itself into a premium product. When a single message can jolt the S&P 500, oil prices, or individual stocks, the gap between traders who see that data first and everyone else can matter. This article looks at three stocks exposed to this new pay to see model, with one potentially positioned on the right side of the trend and...

Sticky inflation, a firm jobs market, and a Federal Reserve that signals it may keep policy tight or even tighten further all put a spotlight on companies tied to AI infrastructure and data centers. Capital spending linked to AI could both support earnings potential and add fresh inflation pressure, so stock selection matters. This article looks at how those macro forces intersect with AI related demand, and highlights three stocks with positive exposure from our AI Infrastructure and Data...

Eton Pharmaceuticals has turned heads with a very large 3 year return and a fresh 52 week run, yet its current checks paint a picture of a stock that screens as expensive rather than a clear bargain. Over the past 3 years, Eton Pharmaceuticals has delivered a very large total return of about 13x. This puts extra focus on whether recent optimism has already been reflected in the share price. Recent momentum around a new FDA approved drug agreement can support expectations for future revenue...

Cleveland-Cliffs stock is coming off a difficult stretch, with the share price down 57.0% over the past 5 years, yet both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and conventional market multiples currently point to the shares trading below what the underlying cash flows may justify. The 57.0% share price decline over 5 years leaves existing holders with a steep loss, while raising the question of whether expectations have swung too far to the pessimistic...

CAVA Group stock has given investors a solid 41.1% gain over the past three years, yet the latest valuation checks and recent share price pullback raise questions about whether the current level still makes sense or now leans expensive. Over the past three years, CAVA Group has returned 41.1%. This puts the recent share price weakness into context as a pause after a stronger multi year run. The planned expansion of the restaurant base can support higher revenue expectations over time. The...

WaFd (WAFD) has put up a clean set of Q3 2026 numbers, with total revenue of about US$194.5 million and basic EPS of roughly US$0.85 feeding into trailing 12 month revenue of about US$761.1 million and EPS of around US$3.17. The company has seen revenue move from about US$721.1 million on a trailing basis in Q3 2025 to roughly US$761.1 million by Q3 2026, while trailing EPS shifted from about US$2.62 to US$3.17, setting the backdrop for investors weighing slower top line growth against firmer...

nLIGHT’s stock has delivered very strong gains over the past few years, yet the latest valuation checks, including an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market multiples, both point to the shares trading at a premium to those fundamentals. Over the last 3 years, nLIGHT has returned about 376.6%, which puts extra focus on whether recent gains are already pricing in much of its future potential. The recent award of a Pentagon contract with funding...

Leadership transition at Napco Security Technologies Napco Security Technologies (NSSC) has announced a leadership transition that shifts founder Richard Soloway from Chief Executive Officer to Founder and Executive Chairman, while long-time executive Kevin Buchel steps into the Chief Executive Officer and President roles. For investors watching Napco Security Technologies stock, the move concentrates day-to-day operational responsibility with Buchel, who has more than 25 years of experience...

Rayonier (NYSE:RYN) has appointed Ryan Daniels as Senior Vice President, Wood Products. Daniels steps into the permanent role after serving as Interim SVP, Wood Products. He previously held operational roles at PotlatchDeltic before its recent merger with Rayonier. Rayonier, trading at about $21.8 per share, is in the middle of integrating its wood products operations following its merger with PotlatchDeltic. The appointment of Ryan Daniels formalizes leadership over one of the company’s...

After a strong three year gain of 107.1%, Hanover Insurance Group no longer looks obviously cheap, and the current checks point to a stock that is priced roughly in line with its fundamentals rather than at a clear bargain. Over the past 3 years, Hanover Insurance Group has returned 107.1%, which puts extra attention on whether recent share price strength is already baking in much of the good news. The recently announced CEO succession plan can support confidence in continuity and execution...

Catalyst Pharmaceuticals stock has delivered a very large 5 year return, yet the latest valuation checks suggest the current price looks roughly in line with what the broader fundamentals support rather than clearly cheap or clearly stretched. Over the past 5 years, Catalyst Pharmaceuticals has returned about 4.6x, which puts extra focus on whether the recent share price now simply reflects the progress already made. The agreed acquisition by Angelini Pharma can support confidence in the...

Brookdale Senior Living Inc. recently reported that for June 2026 its consolidated weighted average occupancy rose to 82.5%, with both month‑end and same‑community measures improving year over year and sequentially. Alongside this operational progress, Brookdale refinanced part of its 2027 debt, extended its revolving credit facility, and acquired the Brookdale Galleria community in Houston using cash and its expanded credit line. We’ll now examine how Brookdale’s improved occupancy and...

Motorola Solutions stock sits at an interesting point where a near doubling in total return over the past five years meets valuation checks that suggest it is no longer an obvious bargain, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to roughly fair pricing while market multiples lean expensive. Over five years, Motorola Solutions has delivered a total return of 97.8%, which puts recent pricing in the context of a long and substantial move. Ongoing demand for mission...

Bank7 (BSVN) has just posted Q2 2026 results, with total revenue of US$22.9 million and basic EPS of US$0.88, set against trailing 12 month revenue of US$97.7 million and EPS of US$4.43 that frame the latest quarter within a steady recent earnings run. Over the last few quarters, revenue has moved between US$22.6 million and US$26.2 million while quarterly EPS has ranged from US$0.88 to US$1.27. This gives investors a clear view of how the current print fits into the recent trend before...

Skyworks Solutions (SWKS) is back in focus as investors weigh upbeat commentary about a possible earnings beat against fresh concerns over margin pressures, customer concentration risks, and a recent analyst downgrade. See our latest analysis for Skyworks Solutions. At a share price of US$59.35, Skyworks Solutions has seen short term momentum soften, with a 30 day share price return down 14.46%, a 1 year total shareholder return down 15.01%, and a 5 year total shareholder return down 64.42%...

In July 2026, WD-40 Company reported third-quarter results showing sales of US$195.12 million and net income of US$30.22 million, alongside continued progress on its share repurchase program that has retired 193,425 shares for US$42.94 million since July 2023. Despite higher nine-month sales of US$511.21 million, net income over the same period edged lower to US$67.99 million, highlighting how rising costs and margin pressure are tempering the benefits of revenue growth. With third-quarter...

Kimberly-Clark (KMB) is in focus after Arbex, its joint venture with Suzano, began operating as an independent tissue and hygiene company serving more than 70 markets worldwide, raising fresh questions for investors. See our latest analysis for Kimberly-Clark. At a share price of $108.35, Kimberly-Clark has seen its 30-day share price return of 6.78% and 90-day share price return of 9.62% contrast with a 1-year total shareholder return that is down 10.88%. This suggests recent momentum has...

Bio-Techne (TECH) stock is in focus after the company reported a softer quarter, with revenue down 1.5% year on year and below analyst expectations, yet the share price has since risen 26.1%. See our latest analysis for Bio-Techne. Over the past month, Bio-Techne’s 31.1% share price return suggests momentum has picked up again. The 39.5% total shareholder return over one year contrasts with weaker total shareholder returns over three and five years, which hints at a recent shift in...